gullapalli

The alliance combines the strengths of OBT’s platform with Roche’s expertise in drug development. Credit: PowerUp/Shutterstock. Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment. The partnership will leverage OBT’s OGAP-Verify discovery […]

The company is focused on developing treatments for acute central nervous system injuries. Credit: Jo Panuwat D/Shutterstock. The US Patent and Trademark Office (USPTO) has allowed two new patents for Remedy Pharmaceuticals’ Cirara to treat large hemispheric infarction (LHI). The

Insight’s ophthalmic imaging bioresource includes 35 million images of the eye. Credit: PeopleImages.com – Yuri A/Shutterstock. Moorfields Eye Hospital’s Insight Health Data Research Hub and insitro have announced a partnership to develop an AI foundation model for the genetic discovery

The company is progressing gene editing medicine through a multi-centre, open-label, Phase I/II trial. Credit: metamorworks/Shutterstock. Arbor Biotechnologies has closed $73.9m in a Series C financing round, earmarked for advancing its gene editing therapeutic pipeline aimed at liver and central

The agreement involves the development of the first oral glucagon-like peptide-1/glucagon dual agonist to offer obesity treatments. Credit: fizkes/Shutterstock. Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral dual

Biogen’s therapy previously secured an orphan drug designation for FA treatment. Credit: Piotr Swat/Shutterstock. Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, progressive neurodegenerative disease, in individuals aged 16 years and above.

AstraZeneca will leverage Alteogen’s platform technology to develop the therapies. Credit: © AstraZeneca 2025. AstraZeneca has entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s hyaluronidase utilising Hybrozyme platform technology, ALT-B4, to develop subcutaneous formulations of several

The company has recently shared Phase I outcomes for an orally administered candidate for non-opioid pain relief. Credit: meeboonstudio/Shutterstock. Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its

Azurity’s mission of serving overlooked individuals is further advanced through the acquisition. Credit: JHVEPhoto/Shutterstock. Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary. The acquisition is aimed at improving Azurity’s medicine delivery offerings

BMS’ Breyanzi has gained approval for several other lymphomas in the EU and other regions. Credit: Piotr Swat/Shutterstock. The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 (CD19)-directed chimeric antigen receptor (CAR)